Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GlycoMimetics, Inc. - Common Stock (NQ: GLYC )

0.2596 +0.0006 (+0.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GlycoMimetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer
From GlycoMimetics, Inc.
Via Business Wire
Why DWAC Is Trading Lower By Around 19%; Here Are 32 Stocks Moving Premarket
Gainers First Wave BioPharma, Inc. (NASDAQ: FWBI) shares rose 39.6% to $4.44 in pre-market trading after gaining 7% on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
  
Via Benzinga
Recap: GlycoMimetics Q2 Earnings
  GlycoMimetics (NASDAQ:GLYC) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap: GlycoMimetics Q1 Earnings
GlycoMimetics (NASDAQ:GLYC) reported its Q1 earnings results on Thursday, April 28, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap: GlycoMimetics Q4 Earnings
GlycoMimetics (NASDAQ:GLYC) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
  
Via Benzinga
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2022
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report Second Quarter Financial Results on August 3, 2022
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Participate at Upcoming Jefferies 2022 Healthcare Conference
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2022
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Earnings Conference Call Is Coming Up, Here's What You Need To Know
GlycoMimetics (NASDAQ:GLYC) will host a conference call at 08:30 AM ET on April 28, 2022, to discuss Q1 2022 earnings results. How to Attend GlycoMimetics (GLYC) Conference Call Follow this link to... 
Via Benzinga
GlycoMimetics to Report First Quarter Financial Results on April 28, 2022
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics's Return On Capital Employed Insights
GlycoMimetics (NASDAQ:GLYC) brought in sales totaling $18.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 0.52%, resulting in a loss... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Tonix Pharmaceuticals (NASDAQ:TNXP) stock rose 49.1% to $0.28 during Thursday's regular session. As of 12:31 EST, Tonix Pharmaceuticals's stock is trading... 
Via Benzinga
63 Biggest Movers From Yesterday
Gainers Indonesia Energy Corporation Limited (NASDAQ: INDO) shares climbed 39.3% to close at $20.20 on Thursday after jumping around 35% on Wednesday. DBV Technologies S.A. (... 
Via Benzinga
A Preview Of GlycoMimetics's Earnings
GlycoMimetics (NASDAQ:GLYC) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Earnings Scheduled For March 3, 2022
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
Via Benzinga
GlycoMimetics to Report Fourth Quarter and 2021 Year-End Financial Results on March 3, 2022
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Appoints Bruce Johnson Senior Vice President and Chief Commercial Officer
From GlycoMimetics, Inc.
Via Business Wire
Two GlycoMimetics Posters at 63rd ASH Annual Meeting Highlight Potential of GMI-1359, a Dual Antagonist of CXCR4 and E-selectin
From GlycoMimetics, Inc.
Via Business Wire
NCI-Sponsored Trial of Uproleselan in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Completes Enrollment of Phase 2 Portion Ahead of Schedule
From GlycoMimetics, Inc.
Via Business Wire
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Appoints Regulatory Veteran Lisa DeLuca as Vice President, Regulatory Affairs
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Completes Enrollment of Phase 3 Registration Trial Evaluating Lead Candidate Uproleselan in Patients with Relapsed /Refractory Acute Myeloid Leukemia (AML)
From GlycoMimetics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 12, 2021
Upgrades For Blink Charging Co (NASDAQ: 
Via Benzinga
18 Stocks Moving In Friday's Pre-Market Session
Gainers NuZee, Inc. (NASDAQ: NUZE) rose 30.3% to $6.89 in pre-market trading after jumping around 165% on Thursday. NuZee manufacturing partner, Cuvee Coffee, reported an... 
Via Benzinga
GlycoMimetics GMI-1359 Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting and Exposition
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Present at Two Upcoming Healthcare Investor Conferences
From GlycoMimetics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS